OR WAIT 15 SECS
AGC adds second biopharma contract manufacturer with acquisition of CMC Biologics.
CMC Biologics, a contract developer and manufacturer of monoclonal antibodies, coagulation factors, and other therapeutic proteins for clinical and commercial applications, announced on Dec. 19, 2016, that it has entered into an agreement with AGC Asahi Glass (AGC) in which AGC will acquire 100% of CMC Biologics’ shares. This acquisition is expected to close in January 2017.
CMC Biologics will retain its brand and independence and does not anticipate changes in operations, the current leadership team, or employee base, as reported in a press statement announcing the deal.
Founded in Denmark in 2001, CMC Biologics now has more than 500 employees, two commercial-phase manufacturing facilities, and one early-phase manufacturing facility.
In September 2016, ACG acquired another biopharmaceutical contract manufacturer, Biomeva, based in Heidelberg, Germany.